A 12-Week, Placebo Controlled Trial of Ziprasidone as Monotherapy for Major Depressive Disorder
A 12-Week, Placebo Controlled Trial of Ziprasidone as Monotherapy for Major Depressive Disorder
This is a study on the effectiveness, tolerability and safety of oral ziprasidone as
 monotherapy in patients with major depressive disorder (MDD). Outpatients suffering from MDD
 will be treated with either ziprasidone or placebo for 12 weeks.

 Hypothesis: There will be a statistically significant difference in the magnitude of
 response, as measured by a decrease in baseline 17-item Hamilton Depression Rating Scale
 (HAM-D-17) scores, between the two treatment groups; the reduction in HAM-D-17 scores will be
 greater in the ziprasidone monotherapy group than in the placebo group.
Exploratory hypothesis 1: There will be a statistically significant difference in the
 percentage of responders in the two treatment groups; response rates will be significantly
 higher for the ziprasidone monotherapy compared to the placebo group.

 Exploratory hypothesis 2: The change in 6-VAS-D scores during the trial will be highly
 correlated to the change in HAM-D-17 and QIDS-SR during the trial.
Inclusion Criteria:

 1. Age 18-65.

 2. Written informed consent.

 3. MDD, current according to the fourth version of the Diagnostic and Statistical Manual
 for Mental Disorders (DSM-IV) as diagnosed by the Mini International Neuropsychiatric
 Interview (MINI; Sheehan et al, 1998).

 4. Quick Inventory of Depressive Symptomatology - Self-Rated (QIDS-SR- Trivedi et al,
 2004) score of at least 10 at both screen and baseline visits.

 Exclusion Criteria:

 1. Pregnant women.

 2. Women of child bearing potential who are not using a medically accepted means of
 contraception (to include oral contraceptive or implant, condom, diaphragm,
 spermicide, intrauterine device, tubal ligation, or a partner with vasectomy).

 3. Treatment with antidepressants for 2 weeks prior to the screen visit. If interested in
 discontinuing their current medication, potential participants must discuss this
 possibility with the prescribing physician. Study doctors will not implement any form
 of treatment washout.

 4. Patients who no longer meet DSM-IV criteria for MDD during the baseline visit, or
 patients who demonstrate a 25% or greater reduction in QIDS-SR scores, screening to
 baseline.

 5. Serious suicide or homicide risk, as assessed by the evaluating clinician or a score
 of 4 on the third item of the HAM-D.

 6. Unstable medical illness including cardiovascular, hepatic, renal, respiratory,
 endocrine, neurological, or hematological disease.

 7. Patients who meet criteria for alcohol or substance dependence, active within the last
 month.

 8. Any bipolar disorder (current or past).

 9. Any psychotic disorder (current or past).

 10. Psychotic features in the current episode or a history of psychotic features.

 11. History of a seizure disorder.

 12. Clinical or laboratory evidence of untreated hypothyroidism.

 13. Patients requiring excluded medications (see table 1 for details).

 14. Prior course of ziprasidone, or intolerance to ziprasidone at any dose.

 15. Any investigational psychotropic drug within the last 3 months.

 16. Patients with significant cardiac conduction problems on screening electrocardiogram
 such as atrial fibrillation, atrial flutter, atrio-ventricular block, prolonged or
 abnormal QTc interval (i.e. QTc>450msec), or prolonged QRS interval.

 17. Patients who have suffered a myocardial infarction within the past 12 months, with
 uncompensated heart failure, or a history of QTc prolongation.

 18. Patients with abnormal serum potassium or magnesium levels upon screening.

 19. Patients currently taking other drugs that prolong the QTc including dofetilide,
 sotalol, quinidine, class Ia antiarrhythmics, class III antiarrhythmics, mesoridazine,
 thioridazine, chlorpromazine, droperidol, pimozide, sparfloxacin, gatifloxacin,
 moxifloxacin, halofantrine, mefloquine, pentamidine, arsenic trioxide, levomethadyl
 acetate, dolasetron methylate, probucol or tacrolimus.

 20. Patients who have failed to experience significant clinical improvement following 3 or
 more antidepressant trials of adequate duration (at least 6 weeks) and dose (minimal
 effective doses defined as: fluoxetine, paroxetine, citalopram 20mg; sertraline,
 fluvoxamine 50mg, escitalopram 10mg, paroxetine CR 25mg, venlafaxine 75mg, duloxetine
 60mg, bupropion 150mg, 15mg of mirtazapine, trazodone or nefazodone 300mg).